Oncoinvent invites for Q3 2025 company update in English on Tuesday 4[th] of November at 08:30 AM CEST. The presentation will be broadcasted live on https://channel.royalcast.com/landingpage/hegnarmedia/20251104_9/. There will be a possibility for Q&A.
Oslo, 3 November 2025: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the “Company”) on 29 October 2025 regarding the completion of the merger between the Company and the former Oncoinvent ASA (reg. no. 995 764 458) (“Oncoinvent”) (the “Merger”).
Oslo, 29 October 2025 – Reference is made to the previous stock exchange announcements made in connection with the combination of BerGenBio ASA and Oncoinvent ASA (“Oncoinvent”) through a statutory triangular merger (the “Merger”), including the announcements made on 4 August 2025 regarding approval of the Merger by the extraordinary general meetings of the two companies. Reference is further made to the stock exchange announcement made on 24 October 2025 regarding key dates for completion of the Merger and the stock exchange announcement made on 28 October 2025 regarding the approval and publication of the prospectus (the “Prospectus”) prepared in connection with the Merger and the contemplated rights issue in the combined company.
Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the presentation of the previously reported final 18-months safety and efficacy results from its Phase 1/2a clinical trial (RAD-18-002) evaluating Radspherin® in patients with peritoneal metastases from colorectal cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies, to be held at the Fira Barcelona October 29-31, 2025. Radspherin®, direct intraperitoneal targeting with the alpha-emitter radium-224, aims to eliminate post-surgery micro-metastases and thereby prevent or delay peritoneal recurrence.
Reference is made to the joint stock exchange announcement made on 24 October 2025 by BerGenBio ASA and Oncoinvent ASA (“Oncoinvent”) regarding key dates for completion of the combination of the two companies through a statutory triangular merger (the “Merger”). Reference is further made to the stock exchange announcement made on 28 October 2025 regarding the approval and publication of the prospectus (the “Prospectus”) prepared in connection with the Merger and the contemplated rights issue in the combined company.
Oslo, 17 September 2025: Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) on 5 August 2025 regarding updated key information relating to the contemplated fully underwritten rights issue in the Company raising gross proceeds of NOK 130 million (the “Rights Issue”). Reference is also made to the stock exchange announcement made by the Company earlier today on 17 September 2025, with updated information regarding the timeline for the Rights Issue and the contemplated combination of the Company, Oncoinvent and BerGenBio Norge AS through a statutory triangular merger (the “Merger”). Updated key information relating to the Rights Issue is set out below.
Oslo, 17 September 2025: Reference is made to the joint stock exchange announcement made on 30 June 2025 by BerGenBio ASA (the “Company”) and Oncoinvent ASA (“Oncoinvent”) regarding the contemplated combination of the Company, Oncoinvent and BerGenBio Norge AS through a statutory triangular merger (the “Merger”). Reference is also made to the stock exchange announcement made by the Company on 30 June 2025 regarding a fully underwritten rights issue (the “Rights Issue”) with preferential subscription rights (the “Subscription Rights”) for the Company’s existing shareholders at the time of completion of the Merger (the “Rights Issue Announcement”).
Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and Oncoinvent ASA, a clinical-stage radiopharmaceutical company, have entered into a strategic agreement for Thorium-228 radioisotopes to supply the Phase 3 clinical program for Radspherin®, Oncoinvent’s lead product candidate.
Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximizing recruitment.
Oncoinvent will present operational and financial update for the first half of 2025 on Wednesday 27 August 2025 at 08:00am (CET). The presentation will be live streamed in English followed by a Q&A session.
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.